Recently approved molecularly targeted therapies in AML

Acute myeloid leukemia is a disease for which, until recently few options were available both for the newly diagnosed and relapsed/refractory patients. In the recent years, several new agents have been approved offering patients more options. Encouragingly, the new agents are targeting molecular aberrations/key proteins sparing the patients from the side effects of the intensive chemotherapy regimens. In this review, we highlight the studies leading to approval of Glasdegib, Venetoclax, Enasidenib, Ivosidenib, and Gilteritinib and we highlight key clinical points. We also outline the challenges that the new agents bring in the clinical practice.